[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353175-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-353175-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","prevalence-and-genotype-distribution-of-human-papillomavirus-in-cervical-cancer-and-precancer-in-japan-between-2012-and-2025-a-retrospective-single-center-study","Prevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study","","Retrospective single-center analysis examined HPV genotype distribution in cervical cancer and precancer in Japan from 2012 to 2025, targeting histologically confirmed CIN2, CIN3, SCC, AIS, ASC, and ADC cases. Cervical exfoliated cell specimens from 2,536 women underwent HPV L1 PCR followed by reverse blot hybridization for genotyping. HPV positivity reached 96.6% overall, with highest detection in CIN2/CIN3/SCC and lower rates in ADC. HPV16 prevalence rose with lesion severity, while HPV52/58 declined. Vaccine-preventable types increased in squamous lesions and remained high in glandular lesions, supporting nonavalent vaccine adoption.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prevalence-and-genotype-distribution-of-human-papillomavirus-in-cervical-cancer-and-precancer-in-japan-between-2012-and-2025-a-retrospective-single-center-study/353175/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prevalence-and-genotype-distribution-of-human-papillomavirus-in-cervical-cancer-and-precancer-in-japan-between-2012-and-2025-a-retrospective-single-center-study/353175.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study?","Question",{"text":63,"@type":64},"To provide updated data on how human papillomavirus (HPV) genotypes are distributed in cervical cancer and precancer in Japan from 2012 to 2025 at a single Tokyo university hospital.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were HPV genotypes tested in the study?",{"text":68,"@type":64},"Cervical exfoliated cell specimens were collected from 2,536 women and analyzed using HPV L1 PCR followed by reverse blot hybridization for HPV genotyping.",{"name":70,"@type":61,"acceptedAnswer":71},"Which HPV type showed the strongest association with disease progression?",{"text":72,"@type":64},"HPV16 infections were the most prevalent in squamous lesions and increased progressively with lesion severity, with prevalence ratio analysis supporting a strong association with progression to invasive cancer.",{"name":74,"@type":61,"acceptedAnswer":75},"What do the findings imply for vaccination in Japan?",{"text":76,"@type":64},"The results highlight the need for widespread adoption of the nonavalent vaccine, because coverage for HPV16/18 and other nonavalent vaccine-related types exceeded 87% in CIN2 and 92% in SCC.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},353175,1790512756,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 12 June 2026  \nDOI 10.3389/fpubh.2026.1857364  \nOPEN ACCESS  \nEDITED BY  \nTullio Golia D'Augè,  \nSapienza University of Rome, Italy  \nREVIEWED BY  \nArnaud John Kombe Kombe, University of Texas Southwestern Medical Center, United States Mehmet Nuri Duran,  \nObstetrics and Gynecology Clinic, Türkiye  \n*CORRESPONDENCE  \nIwao Kukimoto  \n [kukimoto.i@jihs.go.jp](kukimoto.i@jihs.go.jp)  \nRECEIVED 16 April 2026  \nREVISED 19 May 2026  \nACCEPTED 25 May 2026  \nPUBLISHED 12 June 2026  \nCITATION  \nNakamura H, Mori S, Ishii Y, Takeuchi T, Tanaka K, Imai A, Matsui T, Iwata T, Yamagami W and Kukimoto I (2026) Prevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study.  \nFront. Public Health 14:1857364 .  \ndoi: 10.3389/fpubh.2026.1857364  \nCOPYRIGHT  \n© 2026 Nakamura, Mori, Ishii, Takeuchi, Tanaka, Imai, Matsui, Iwata, Yamagami and Kukimoto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPrevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study  \nHiromi Nakamura 1, Seiichiro Mori 1, Yoshiyuki Ishii 1,  \nTakamasa Takeuchi 1, Kohsei Tanaka 2, Airi Imai 2, Tomoya Matsui 2, Takashi Iwata 2, Wataru Yamagami 2 and Iwao Kukimoto 1*  \n1Pathogen Genomics Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan, 2Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan  \nObjective: This study aimed to provide the latest data on the distribution of human papillomavirus (HPV) genotypes in cervical cancer and precancer at a single university hospital in Tokyo, Japan, between 2012 and 2025.  \nMethods: Cervical exfoliated cell specimens collected from 2,536 women with histologically confirmed, cervical intraepithelial neoplasia 2 (CIN2), CIN3, squamous cell carcinoma (SCC), adenocarcinoma in situ (AIS), adenosquamous cell carcinoma (ASC), and adenocarcinoma (ADC), were tested by HPV L1 PCR followed by reverse blot hybridization for HPV genotyping.  \nResults: Overall, HPV positivity was 96.6%, with high detection rates in CIN2 (98.5%), CIN3 (98.2%), and SCC (96.1%), and slightly lower rates in ADC (78.3%) . In squamous lesions, HPV16 infections were the most prevalent and increased progressively with lesion severity (33.2% in CIN2, 50.1% in CIN3, 61.7% in SCC) . Prevalence ratio analysis demonstrated a significantly higher prevalence of HPV16 in CIN3 versus CIN2 and in SCC versus CIN3, supporting its strong association with progression to invasive cancer. In contrast, HPV52 and HPV58 infections decreased with disease progression. In glandular lesions, HPV16 and HPV18 predominated across AIS, ASC, and ADC. Among ADC subtypes, usual-type ADC showed the highest HPV positivity (89.8%), whereas endometrioid, minimal deviation, serous, and clear-cell subtypes showed low or absent HPV positivity, highlighting the etiologic heterogeneity of ADC. Among single-type infection cases, the proportion of lesions attributable to vaccine-preventable types (HPV16/18) increased with severity in squamous lesions (31 .9% in CIN2 to 72.2% in SCC) and remained consistently high in glandular lesions (>94%) . Regarding HPV16/18/31/33/45/52/58, potential coverage exceeded 87% in CIN2 and 92% in SCC. Conclusion: These findings confirm the central role of HPV16 in cervical carcinogenesis, and highlight the contribution of HPV52 and HPV58 in precancerous lesions, which further u","cbCaij2RUu8ZOMTt","https://ap.wps.com/l/cbCaij2RUu8ZOMTt","pdf",1533167,"English","# Objective\n# Methods\n# Results\n# Conclusion\n# Introduction\n## High-risk HPV types and vaccination targets\n## Histological subtype differences and progression pathways","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To provide updated data on how human papillomavirus (HPV) genotypes are distributed in cervical cancer and precancer in Japan from 2012 to 2025 at a single Tokyo university hospital.\"},{\"question\":\"How were HPV genotypes tested in the study?\",\"answer\":\"Cervical exfoliated cell specimens were collected from 2,536 women and analyzed using HPV L1 PCR followed by reverse blot hybridization for HPV genotyping.\"},{\"question\":\"Which HPV type showed the strongest association with disease progression?\",\"answer\":\"HPV16 infections were the most prevalent in squamous lesions and increased progressively with lesion severity, with prevalence ratio analysis supporting a strong association with progression to invasive cancer.\"},{\"question\":\"What do the findings imply for vaccination in Japan?\",\"answer\":\"The results highlight the need for widespread adoption of the nonavalent vaccine, because coverage for HPV16/18 and other nonavalent vaccine-related types exceeded 87% in CIN2 and 92% in SCC.\"}]","Prevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study | PDF",1790103424,25,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9dd8b80b94d848c317d09ae48d934e4.webp",983,1390,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2288764efddc66ede3ed237958670bc0.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95cab39b5d9e39478f4f6904abb9cd12.webp",981,1387,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8cc9323f6d905fdab4ac54ec8cf03a1.webp",980,1385]